Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs 10X Genomics Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.43, while 10X Genomics Inc trades at $58 (market cap $7.52B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | TXG | |
|---|---|---|
52-Week High | $112.91 | $58.57 |
52-Week Low | $105.96 | $11.34 |
Market Cap | — | $7.52B |
Sector | — | Health |
Enterprise Value | — | $7.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $106.12 with minimal daily movement (+0.15%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts ranging from $0.38 to $0.46 per share. Market focus remains on inflation data and Federal Reserve policy amid ongoing Middle East tensions affecting bond yields.
Investment-grade corporate bond ETFs face headwinds from rising Treasury yields and inflation concerns. LQD's stability in dividend payments provides income appeal, but technical weakness suggests cautious near-term positioning. Key risks include interest rate sensitivity and geopolitical volatility impacting fixed income markets.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
